Implementation and evaluation in a programmatic setting of a short (6 months), all-oral novel regimen being studied in TB PRACTECAL, consisting of a backbone of Bedaquiline (B), Pretomanid (Pa) and tapered dose Linezolid (LZD) for treatment of RR TB.